Study: Drug given during PCI lowers bleeding risk

10/18/2011 | MedPage Today (free registration)

A trial of more than 8,000 patients led by New York University School of Medicine researchers found bivalirudin administered during PCI saw a decreased bleeding risk compared with the use of heparin or heparin combined with glycoprotein IIb-IIIa inhibitors. Researchers also found no increase in thrombotic or ischemic issues in the 12 months following PCI where bivalirudin was used. The results were published in the journal Circulation: Cardiovascular Interventions.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC